[1]Wang XW, Zhou X, Zeng FY, et al. miR-485-5p inhibits the progression of breast cancer cells by negatively regulating MUC1[J]. Breast Cancer, 2020, 27: 765-775. [2]Wu B, Lu ST, Zhang LJ, et al. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment[J]. Int J Nanomedicine, 2017, 12: 1853-1862. [3]Zhao HJ, Shi PC, Deng MM, et al. Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption[J]. Oncotarget, 2016, 7: 85515-85528. [4]Fan YP, Liao JZ, Lu YQ, et al. miR-375 and Doxorubicin co-delivered by liposomes for combination therapy of hepatocellular carcinoma[J]. Mol Ther Nucleic Acids, 2017, 7: 181-189. [5]Al-malky HS, Al-harthi SE, Osman AMM. Major obsta-cles to doxorubicin therapy: Cardiotoxicity and drug resistance[J]. J Oncol Pharm Pract, 2020, 26: 434-444. [6]Gao H, Zhang Y, Dong L, et al. Triptolide induces autophagy and apoptosis through ERK activation in human breast cancer MCF-7 cells[J]. Exp Ther Med, 2018, 15: 3413-3419. [7]Deng Y, Li FL, He PL, et al. Triptolide sensitizes breast cancer cells to doxorubicin through the DNA damage response inhibition[J]. Mol Carcinog, 2018, 57: 807-814. [8]Mohajeri M, Sahebkar A. Protective effects of curcumin against doxorubicin-induced toxicity and resistance: a review[J]. Crit Rev Oncol Hematol, 2018, 122: 30-51. [9]Zhao F, Huang WW, Zhang Z, et al. Triptolide induces protective autophagy through activation of the CaMKKβ-AMPK signaling pathway in prostate cancer cells[J]. Oncotarget, 2016, 7: 5366-5382. [10]Chang WT, Kang JJ, Lee KY, et al. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway[J]. J Biol Chem, 2001, 276: 2221-2227. [11]刘倩,汤建华,张志华.雷公藤甲素对非小细胞肺癌细胞系A549增殖的抑制和凋亡的诱导[J].基础医学与临床,2020,40:315-320. [12]杨芒庄,杨旭东,王晓龙.Circ-MALAT1靶向miR-101抑制膀胱癌细胞系SW780侵袭和迁移[J].基础医学与临床,2022,42:472-478. |